Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (GLSI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GLSI · as of Sep 30, 2025
Ownership Breakdown
51
Institutional Holders
$12.08M
Total Inst. Value
▲ $909,271 vs Q2
14.68M
Shares Outstanding
freeFloat 47.39%
1.21M
13F Shares Held
▼ 17,489 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GLSI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 363.3K | 2.72% | 2.72% | $3.61B | Nov 12, 2025 | ▼ 3.9K |
VANGUARD GROUP INC pharmaceutical preparations | 282.2K | 2.11% | 2.11% | $2.81B | Nov 7, 2025 | ▲ 13.2K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 142.1K | 1.06% | 1.06% | $1.41B | Nov 12, 2025 | ▲ 3.1K |
STATE STREET CORP pharmaceutical preparations | 81.9K | 61.29% | 61.29% | $815.36M | Nov 14, 2025 | ▼ 301 |
NORTHERN TRUST CORP pharmaceutical preparations | 75.9K | 56.77% | 56.77% | $755.25M | Nov 14, 2025 | ▼ 6.9K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 38.4K | 28.72% | 28.72% | $382.08M | Nov 13, 2025 | ▲ 11.1K |
MARSHALL WACE, LLP pharmaceutical preparations | 32.1K | 23.97% | 23.97% | $318.91M | Nov 13, 2025 | ▼ 24.1K |
DEUTSCHE BANK AG\ pharmaceutical preparations | 21.5K | 16.08% | 16.08% | $213.94M | Nov 13, 2025 | NEW |
CITADEL ADVISORS LLC pharmaceutical preparations | 20.9K | 15.66% | 15.66% | $208.37M | Nov 14, 2025 | ▲ 7.2K |
STRS OHIO pharmaceutical preparations | 20.0K | 14.96% | 14.96% | $199.00M | Oct 30, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
16
Increased
+42.9K shares4
New Positions
first time holders14
Decreased
−64.1K shares0
Sold Out
fully exitedNet shares change (top 50)
21.2K
+42.9K / −64.1K
Net new holders
+6
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GLSI insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Patel Snehal CEO and CFO | Jan 13, 2026 | Purchase | 1,800 | $29.83 | $53.7K | 5.60M | Form 4 ↗ |
Patel Snehal CEO and CFO | Jan 12, 2026 | Purchase | 2,900 | $27.54 | $79.9K | 5.60M | Form 4 ↗ |
Patel Snehal CEO and CFO | Dec 31, 2025 | Purchase | 4,300 | $21.36 | $91.8K | 5.60M | Form 4 ↗ |
Patel Snehal CEO and CFO | Dec 30, 2025 | Purchase | 2,900 | $21.73 | $63.0K | 5.60M | Form 4 ↗ |
Patel Snehal CEO and CFO | Dec 18, 2025 | Purchase | 4,100 | $12.62 | $51.7K | 5.59M | Form 4 ↗ |
Patel Snehal CEO and CFO | Nov 25, 2025 | Purchase | 4,600 | $8.37 | $38.5K | 5.59M | Form 4 ↗ |
Patel Snehal CEO and CFO | Nov 13, 2025 | Award | 100,000 | $8.20 | $820.0K | 2.35M | Form 4 ↗ |
Patel Snehal CEO and CFO | Nov 7, 2025 | Purchase | 10,600 | $8.43 | $89.4K | 5.58M | Form 4 ↗ |
Patel Snehal CEO and CFO | Oct 31, 2025 | Purchase | 2,300 | $9.26 | $21.3K | 5.57M | Form 4 ↗ |
Patel Snehal CEO and CFO | Apr 25, 2025 | Purchase | 3,600 | $9.88 | $35.6K | 5.57M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Greenwich LifeSciences, Inc. (GLSI) is primarily owned by institutional investors, who hold approximately 8.3% of total shares outstanding. Company insiders own approximately 52.61%, while retail and public investors account for the remaining 39.11%.
The largest institutional shareholder of Greenwich LifeSciences, Inc. is BLACKROCK, INC., holding approximately 363,299 shares — equal to 2.72% of outstanding shares — as of September 30, 2025.
A total of 51 institutional investors currently hold GLSI stock, with a combined institutional value of approximately $12,081,502 as of the most recent 13F filing period.
Frequently asked questions
GLSI ownershipGreenwich LifeSciences, Inc. (GLSI) is primarily owned by institutional investors, who hold approximately 8.3% of shares. The largest shareholder is BLACKROCK, INC. with a 2.72% stake. Company insiders hold 52.61%. Data sourced from SEC Form 13F as of September 30, 2025.